GLP-1 Market
LLY $1184.78 ▲ +0.1% NVO $38.71 ▼ -0.2% PFE $28.72 ▲ +0.2% VKTX $33.03 ▼ -7.1% KLRA $11.12 ▼ -0.9% GPCR $35.06 ▼ -2.4% RHHBY $53.34 ▼ -2.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Olanzapine

Company
Centre for Addiction and Mental Health
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
31 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

31 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 29, 2026

Find a Clinical Trial Near Me

See recruiting studies for Olanzapine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01246765

    National Pregnancy Registry for Psychiatric Medications

    Massachusetts General Hospital 5000 participants Est. completion 2033-12 1 site
    Other conditions: Pregnant Women, Psychotropic Drugs
    View official trial listing →
  • Recruiting NCT NCT04478838

    "Extended" (Alternate Day) Antipsychotic Dosing

    Not yet reported Centre for Addiction and Mental Health 120 participants Est. completion 2028-09-30 1 site Stand-alone
    Other conditions: Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy, Antipsychotic Agents
    View official trial listing →
  • Recruiting NCT NCT05635227

    Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery

    Not yet reported Rigshospitalet, Denmark 1200 participants Est. completion 2028-02 1 site Stand-alone
    Cardiovascular disease Other conditions: Aortic Valve Disease
    View official trial listing →
  • Recruiting NCT NCT05669742

    Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

    Not yet reported Tanta University 40 participants Est. completion 2026-12 1 site
    Other conditions: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
    View official trial listing →
  • Recruiting NCT NCT05705492

    Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

    Not yet reported OHSU Knight Cancer Institute 66 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05814640

    Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

    Not yet reported, Not yet reported First Affiliated Hospital of Chongqing Medical University 520 participants Est. completion 2027-07-01 1 site Stand-alone
    Other conditions: Depression, Sequestra
    View official trial listing →
  • Recruiting NCT NCT06049953

    Maternal And Infant Antipsychotic Study

    Icahn School of Medicine at Mount Sinai 74 participants Est. completion 2028-01-01 1 site
    Other conditions: Antipsychotics, Pregnancy
    View official trial listing →
  • Recruiting NCT NCT06200168

    Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

    Not yet reported Jiuda Zhao 370 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting
    View official trial listing →
  • Recruiting NCT NCT06338683

    Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

    Not yet reported Qinghai Red Cross Hospital 230 participants Est. completion 2028-03-20 1 site Stand-alone
    Other conditions: Advanced Cancer, Olanzapine, Progression Free Survival
    View official trial listing →
  • Recruiting NCT NCT06482554

    Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

    Not yet reported Louisiana State University Health Sciences Center Shreveport 80 participants Est. completion 2026-12 1 site
    Other conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
    View official trial listing →
  • Recruiting NCT NCT06554613

    Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

    Not yet reported Second Affiliated Hospital of Nanchang University 156 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06588413

    Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

    Not yet reported Augusta University 172 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: Multiple Myeloma, Autologous Stem Cell Transplantation
    View official trial listing →
  • Recruiting NCT NCT06613334

    Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses

    Not yet reported Centre Hospitalier St Anne 200 participants Est. completion 2027-10 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT06740890

    Exercise and Olanzapine-samidorphan

    Not yet reported New York State Psychiatric Institute 30 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
    View official trial listing →
  • Recruiting NCT NCT06821945

    A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia

    Not yet reported Boryung Pharmaceutical Co., Ltd 120 participants Est. completion 2027-05 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT06850454

    Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy

    Not yet reported Mahidol University 140 participants Est. completion 2026-01-31 1 site Stand-alone
    Other conditions: Chemotherapy Induced Nausea and Vomiting
    View official trial listing →
  • Recruiting NCT NCT06952920

    Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer

    Not yet reported Jiuda Zhao 388 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster
    View official trial listing →
  • Recruiting NCT NCT06995508

    Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

    Not yet reported Roswell Park Cancer Institute 66 participants Est. completion 2031-11-15 1 site Stand-alone
    Other conditions: Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
    View official trial listing →
  • Recruiting NCT NCT07208305

    Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

    Not yet reported Affiliated Hospital of Qinghai University 222 participants Est. completion 2027-12-30 1 site
    Other conditions: Nausea, Vomiting
    View official trial listing →
  • Recruiting NCT NCT07246187

    Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

    Not yet reported Mercy Bon Secours Saint Vincent Medical Center 114 participants Est. completion 2026-11 1 site
    Other conditions: Cannabinoid Hyperemesis Syndrome
    View official trial listing →
  • Recruiting NCT NCT07263191

    A Study of Olanzapine in Participants With Bipolar Disorder.

    Boryung Pharmaceutical Co., Ltd 3000 participants Est. completion 2027-09 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Recruiting NCT NCT07413809

    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

    Not yet reported The Affiliated People's Hospital of Ningbo University 92 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07455955

    Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile

    Not yet reported Chinese University of Hong Kong 200 participants Est. completion 2028-07-03 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07482891

    An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC

    Not yet reported Shanghai 6th People's Hospital 200 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Recruiting NCT NCT07565428

    Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

    Not yet reported Minerva Neurosciences 380 participants Est. completion 2028-12 13 sites Stand-alone
    Other conditions: Negative Symptoms of Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT07606014

    No Guts No Glory Probiotics

    Not yet reported, Not yet reported University Medical Center Groningen 112 participants Est. completion 2029-05-01 3 sites
    Other conditions: Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
    View official trial listing →
  • Recruiting NCT NCT07633236

    Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy

    Not yet reported Blokhin's Russian Cancer Research Center 100 participants Est. completion 2027-05-31 1 site Stand-alone
    Other conditions: Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
    View official trial listing →
  • Recruiting NCT NCT07699276

    Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

    Not yet reported Mahidol University 95 participants Est. completion 2027-11-15 1 site Stand-alone
    Other conditions: Cancer (Solid Tumors), Vomiting, Cisplatin, Olanzapine
    View official trial listing →
  • Recruiting NCT NCT07716189

    Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 74 participants Est. completion 2026-12-12 1 site
    Other conditions: Nausea and Vomiting Caused by Trastuzumab Deruxtecan
    View official trial listing →
  • Recruiting NCT NCT07716228

    Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound

    Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 74 participants Est. completion 2026-12-12 1 site
    Other conditions: Nausea and Vomiting Caused by Chemotherapy
    View official trial listing →
  • Recruiting NCT NCT07743827

    Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors

    Not yet reported Alexandria University 90 participants Est. completion 2027-10-15 1 site Stand-alone
    Other conditions: Olanzapine, Breast Cancer, Dexamethasone
    View official trial listing →
  • Completed NCT NCT00000373

    Treatment of Obsessive-Compulsive Disorder

    Not yet reported University of Florida 74 participants Est. completion 2003-07 2 sites
    Other conditions: Obsessive-Compulsive Disorder
    View official trial listing →
  • Completed NCT NCT00000374

    Treatment for First-Episode Schizophrenia

    Not yet reported Northwell Health 125 participants Est. completion 2007-05 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00001656

    Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders

    Not yet reported National Institute of Mental Health (NIMH) 25 participants Est. completion 2008-06 1 site
    Other conditions: Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT00006195

    Glucose Regulation During Risperidone and Olanzapine Treatment

    Not yet reported National Center for Research Resources (NCRR) 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00014001

    CATIE- Schizophrenia Trial

    Not yet reported National Institute of Mental Health (NIMH) 1600 participants Est. completion 2004-12 54 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00015548

    CATIE-Alzheimer's Disease Trial

    Not yet reported National Institute of Mental Health (NIMH) 450 participants Est. completion 2004-10 34 sites
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Completed NCT NCT00034580

    Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

    Not yet reported Eli Lilly and Company 326 participants Est. completion 2002-08 21 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00034801

    Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 378 participants Est. completion 2003-03 30 sites
    Other conditions: Depression, Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00034892

    CAFE Comparison of Atypicals in First Episode of Psychosis

    Not yet reported AstraZeneca Est. completion 2005-03 26 sites
    Other conditions: Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
    View official trial listing →
  • Completed NCT NCT00036088

    Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

    Not yet reported Eli Lilly and Company 530 participants Est. completion 2002-07 60 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00044655

    Switching Medication to Treat Schizophrenia

    Not yet reported Icahn School of Medicine at Mount Sinai 219 participants Est. completion 2009-03
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00048802

    Treatment and Outcome of Early Onset Bipolar Disorder

    Not yet reported Northwell Health 40 participants Est. completion 2006-08 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00048828

    Treating Drug-Resistant Childhood Schizophrenia

    Not yet reported Northwell Health 41 participants Est. completion 2006-06 3 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00050206

    Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder

    Not yet reported Eli Lilly and Company 130 participants Est. completion 2005-05 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00051298

    Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

    Not yet reported Eli Lilly and Company 107 participants Est. completion 2005-04 25 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00053703

    Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

    Not yet reported University of North Carolina, Chapel Hill 116 participants Est. completion 2007-05 4 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00056472

    Study of Pharmacotherapy of Psychotic Depression

    Not yet reported Weill Medical College of Cornell University 259 participants Est. completion 2008-06 4 sites
    Other conditions: Major Depressive Disorder With Psychotic Features
    View official trial listing →
  • Completed NCT NCT00057408

    A Controlled Study of Olanzapine in Children With Autism

    Not yet reported FDA Office of Orphan Products Development 78 participants Est. completion 2005-09 1 site Stand-alone
    Other conditions: Autistic Disorder
    View official trial listing →
  • Completed NCT NCT00065273

    Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay

    Not yet reported Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 50 participants Est. completion 2001-06 1 site
    Other conditions: Mental Retardation, Developmental Delay Disorder
    View official trial listing →
  • Terminated NCT NCT00071253

    Depakote Monotherapy, Olanzapine Monotherapy, and Combination Therapy of Depakote Plus Olanzapine in Stable Subjects During the Maintenance Phase of Bipolar Illness

    Not yet reported Abbott 180 participants 15 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00077714

    Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 12 participants Est. completion 2005-01
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00078039

    Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 630 participants Est. completion 2005-01
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00083668

    Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 619 participants Est. completion 2005-05
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00088036

    Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder

    Not yet reported Eli Lilly and Company 450 participants Est. completion 2006-01 15 sites
    Other conditions: Borderline Personality Disorder
    View official trial listing →
  • Completed NCT NCT00088049

    Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

    Not yet reported Eli Lilly and Company 560 participants Est. completion 2007-07 24 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00088465

    Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

    Not yet reported Eli Lilly and Company 931 participants Est. completion 2010-12 92 sites Stand-alone
    Other conditions: Schizophrenic Disorders, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00088478

    Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 402 participants Est. completion 2005-04 37 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00088491

    Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 1205 participants Est. completion 2006-10 4 sites
    Other conditions: Schizophrenic Disorders
    View official trial listing →
  • Completed NCT NCT00089869

    A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

    Not yet reported, Not yet reported Eli Lilly and Company 20 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00091650

    Olanzapine in Patients With Borderline Personality Disorder

    Not yet reported Eli Lilly and Company 300 participants Est. completion 2005-11 39 sites
    Other conditions: Borderline Personality Disorder
    View official trial listing →
  • Completed NCT NCT00094549

    Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

    Not yet reported Eli Lilly and Company 500 participants Est. completion 2006-12 42 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00094640

    Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

    Not yet reported Eli Lilly and Company 8 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00095524

    Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 300 participants Est. completion 2006-08 32 sites
    Other conditions: Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
    View official trial listing →
  • Completed NCT NCT00100776

    Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

    Not yet reported Eli Lilly and Company 600 participants Est. completion 2005-11 33 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00108368

    The Effects of Risperidone and Olanzapine on Thinking

    Not yet reported US Department of Veterans Affairs Est. completion 2006-03 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00113594

    Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

    Not yet reported Eli Lilly and Company 100 participants Est. completion 2006-03 17 sites
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT00124930

    Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

    Not yet reported Alberta Health services 80 participants Est. completion 2008-06 1 site
    Other conditions: Nausea, Neoplasms
    View official trial listing →
  • Completed NCT NCT00129220

    Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

    Not yet reported Eli Lilly and Company 224 participants Est. completion 2009-01 16 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00143182

    9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)

    Not yet reported Organon and Co 504 participants Est. completion 2006-06-28
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00145444

    Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

    Not yet reported Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 100 participants Est. completion 2005-11 7 sites
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00145496

    Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)

    Not yet reported Organon and Co 468 participants Est. completion 2008-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00148564

    Energy Homeostasis Under Treatment With Atypical Antipsychotics

    Not yet reported Charite University, Berlin, Germany 40 participants Est. completion 2007-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00149292

    Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

    Not yet reported Denovo Biopharma LLC 195 participants Est. completion 2006-07-17 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00149734

    Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

    Not yet reported University of Colorado, Denver 8 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00150215

    A First In Human Study Of PF-00184562 In Healthy Volunteers

    Not yet reported Pfizer 18 participants Est. completion 2005-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00151424

    Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)

    Not yet reported Organon and Co 277 participants Est. completion 2006-02-06
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00156091

    Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

    Not yet reported Organon and Co 260 participants Est. completion 2007-06
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00156117

    Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)

    Not yet reported Organon and Co 417 participants Est. completion 2006-05-30
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00159744

    3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)

    Not yet reported Organon and Co 488 participants Est. completion 2006-04-29
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00159770

    Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients

    Not yet reported Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 290 participants Est. completion 2004-09 43 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00159783

    40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

    Not yet reported Organon and Co 218 participants Est. completion 2007-04
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00159796

    3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

    Not yet reported Organon and Co 489 participants Est. completion 2006-04-28
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00169065

    Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

    Not yet reported Harvard Medical School (HMS and HSDM) 38 participants Est. completion 2002-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00169702

    The Effect of a Weight Management Program During Treatment With Olanzapine

    Not yet reported Heinrich-Heine University, Duesseldorf 100 participants Est. completion 2007-07 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00176436

    Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

    Not yet reported University of Maryland, Baltimore 40 participants Est. completion 2008-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00177164

    Risperdal Consta for Bipolar Disorder

    Not yet reported University of Pittsburgh 50 participants Est. completion 2009-12 4 sites
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00177567

    Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

    Not yet reported University of Pittsburgh 60 participants Est. completion 2004-01 2 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00179062

    Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

    Not yet reported Vanderbilt University 300 participants Est. completion 2007-06 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00179231

    Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia

    Not yet reported Vanderbilt University 80 participants Est. completion 2004-02
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00181935

    Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder

    Not yet reported Massachusetts General Hospital 40 participants Est. completion 2004-07 1 site
    Other conditions: Bipolar Disorder, Mania
    View official trial listing →
  • Completed NCT NCT00182013

    Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder

    Not yet reported Massachusetts General Hospital 106 participants
    Other conditions: Bipolar Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT00182442

    Cognition, Functioning and Quality of Life

    Not yet reported Hamilton Health Sciences Corporation 80 participants Est. completion 2006-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00182507

    Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

    Not yet reported Hamilton Health Sciences Corporation 34 participants Est. completion 2006-03 1 site
    Other conditions: Trichotillomania
    View official trial listing →
  • Completed NCT NCT00183404

    Long-Term Olanzapine Treatment in Children With Autism

    Not yet reported, Not yet reported Drexel University 32 participants Est. completion 2011-10 1 site Stand-alone
    Other conditions: Autism
    View official trial listing →
  • Terminated NCT NCT00183612

    Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

    Not yet reported Massachusetts General Hospital 68 participants Est. completion 2007-04 2 sites
    Other conditions: Bipolar Disorder, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00183625

    Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

    Not yet reported University of California, Los Angeles 107 participants Est. completion 2006-09 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00186017

    Short Term Rescue Study of Olanzapine

    Not yet reported Stanford University 50 participants Est. completion 2010-06 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00188942

    A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder

    Not yet reported University Health Network, Toronto 42 participants Est. completion 2009-06 2 sites
    Other conditions: Major Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00190749

    Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

    Not yet reported Eli Lilly and Company 130 participants Est. completion 2008-06 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00191399

    Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

    Not yet reported Eli Lilly and Company 150 participants Est. completion 2006-03 10 sites
    Other conditions: Depression, Bipolar
    View official trial listing →
  • Completed NCT NCT00191555

    Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment

    Not yet reported Eli Lilly and Company 360 participants Est. completion 2006-05 62 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00191828

    A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme

    Not yet reported Eli Lilly and Company 60 participants Est. completion 2005-08 1 site
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00191997

    Optimal Length of Treatment Continuation With Olanzapine After Remission of Manic or Mixed Episode

    Not yet reported Eli Lilly and Company 180 participants Est. completion 2006-03 11 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00193713

    Bifeprunox in the Treatment of Schizophrenia

    Not yet reported Solvay Pharmaceuticals Est. completion 2006-11
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00194064

    Pilot Study Evaluating the Safety and Efficacy of Open-Label Olanzapine

    Not yet reported University Hospitals Cleveland Medical Center 18 participants Est. completion 2006-02 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00202293

    Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

    Not yet reported Melbourne Health 83 participants Est. completion 2015-11-01 1 site Stand-alone
    Other conditions: Bipolar Disorder, Schizoaffective Disorder
    View official trial listing →
  • Terminated NCT NCT00203307

    A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

    Not yet reported Thomas Jefferson University 3 participants Est. completion 2006-06 1 site
    Other conditions: Migraine
    View official trial listing →
  • Completed NCT NCT00205699

    Metabolic Effects of Antipsychotics in Children

    Not yet reported Washington University School of Medicine 144 participants Est. completion 2011-07 1 site
    Other conditions: Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00205725

    Pfizer/IVGTT/Ziprasidone/Olanzapine

    Not yet reported Washington University School of Medicine 120 participants Est. completion 2006-10 1 site
    Type 2 diabetes Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00205738

    Janssen - Glucose Regulation/Risp/Olanz

    Not yet reported Washington University School of Medicine 120 participants Est. completion 2006-10 1 site
    Type 2 diabetes Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00210769

    A Study of the Long-term Safety and Tolerability and the Long-term Effectiveness of Extended-release Oral Paliperidone in Patients Diagnosed With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 203 participants Est. completion 2005-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00211562

    Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids

    Not yet reported Augusta University 20 participants 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00212771

    Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)

    Not yet reported Organon and Co 440 participants Est. completion 2006-10
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00212784

    Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)

    Not yet reported Organon and Co 1225 participants Est. completion 2006-03-15
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00212836

    Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)

    Not yet reported Organon and Co 481 participants Est. completion 2007-08-02
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00216632

    A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

    Not yet reported Janssen Pharmaceutica N.V., Belgium 99 participants Est. completion 2007-07
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Withdrawn NCT NCT00221481

    An Evaluation of Divalproex vs. Olanzapine for Alcohol Abuse Relapse Prevention in Patients With Bipolar Disorder

    Not yet reported Mayo Clinic Est. completion 2006-03 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00222495

    A Comparative Study of New Medications for Psychosis in Adolescents

    Not yet reported University of Minnesota 30 participants Est. completion 2006-08 1 site
    Other conditions: Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
    View official trial listing →
  • Completed NCT NCT00223418

    Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

    Not yet reported The University of Texas Health Science Center at San Antonio 43 participants Est. completion 2007-06 1 site
    Other conditions: Schizophenia Disorder, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00225498

    Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade

    Not yet reported Northwell Health 35 participants Est. completion 2008-10 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00230828

    Patient-reported Outcomes in the Treatment of Schizophrenia

    Not yet reported Solvay Pharmaceuticals
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00231335

    Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia

    Not yet reported Emory University 30 participants Est. completion 2007-07
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00235352

    Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

    Not yet reported, Not yet reported North Suffolk Mental Health Association 105 participants Est. completion 2007-02 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00236379

    A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder

    Not yet reported Janssen, LP 59 participants Est. completion 2003-08 Stand-alone
    Other conditions: Schizophrenia, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00236457

    A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 629 participants Est. completion 2002-12
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00237861

    Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia

    Not yet reported Yale University
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00237913

    Schizophrenia Trial of Aripiprazole

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 700 participants Est. completion 2005-08 33 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00245206

    Side Effects of Newer Antipsychotics in Older Adults

    Not yet reported Veterans Medical Research Foundation 406 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Schizophrenia, Alzheimer's Disease, Dementia
    View official trial listing →
  • Completed NCT NCT00246259

    A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

    Not yet reported Janssen-Ortho Inc., Canada 77 participants Est. completion 2008-12 11 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00255879

    Movement Disorders Caused by Antipsychotic Drugs in Older Patients

    Not yet reported University of California, San Diego 250 participants Est. completion 2004-08 1 site
    Other conditions: Dyskinesia, Drug-Induced
    View official trial listing →
  • Completed NCT NCT00259870

    SB-773812 Administered In Adults With Schizophrenia

    Not yet reported GlaxoSmithKline 338 participants Est. completion 2007-08 45 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00260962

    Olanzapine in the Treatment of Patients With Anorexia Nervosa

    Not yet reported Ottawa Hospital Research Institute 34 participants Est. completion 2006-09 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT00265343

    6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

    Not yet reported Organon and Co 306 participants Est. completion 2008-01
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00265551

    Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 300 participants Est. completion 2007-01 35 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00266630

    Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

    Not yet reported Eli Lilly and Company 139 participants Est. completion 2009-05 11 sites Stand-alone
    Other conditions: Manic or Mixed Episode Associated With Bipolar I Disorder
    View official trial listing →
  • Terminated NCT NCT00272025

    Treatment Resistant Bipolar Depression

    Not yet reported Queen's University 1 participants Est. completion 2010-01 1 site
    Other conditions: Bipolar Depression
    View official trial listing →
  • Withdrawn NCT NCT00273624

    Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial

    Not yet reported University Hospital Freiburg Est. completion 2009-12 1 site Stand-alone
    Other conditions: Therapy-resistant Depression
    View official trial listing →
  • Completed NCT NCT00275301

    PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

    Not yet reported University of Minnesota 19 participants Est. completion 2008-12 1 site Stand-alone
    Other conditions: Borderline Personality Disorder
    View official trial listing →
  • Completed NCT NCT00287352

    Study of Amantadine for Weight Stabilization During Olanzapine Treatment

    Not yet reported University of North Carolina, Chapel Hill 40 participants Est. completion 2009-09 1 site
    Other conditions: Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
    View official trial listing →
  • Completed NCT NCT00287820

    Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

    Not yet reported Nathan Kline Institute for Psychiatric Research 46 participants Est. completion 2007-09 1 site
    Metabolic syndrome Other conditions: Schizophrenia, Diabetes, Hyperglycemia
    View official trial listing →
  • Completed NCT NCT00290121

    Appetite Increase in Schizophrenia Patients Treated With Atypical Antipsychotics

    Not yet reported Université de Montréal 25 participants Est. completion 2008-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00297960

    Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle

    Not yet reported Medical University of Vienna 1 site
    Other conditions: Healthy Male Volunteers
    View official trial listing →
  • Completed NCT NCT00303602

    Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

    Not yet reported Eli Lilly and Company 149 participants Est. completion 2007-12 21 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00304616

    SWitching to Abilify Trial (SWAT)

    Not yet reported Korea Otsuka Pharmaceutical Co., Ltd. 500 participants Est. completion 2007-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00312598

    Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine

    University of North Carolina, Chapel Hill 30 participants Est. completion 2010-04
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
    View official trial listing →
  • Completed NCT NCT00316238

    A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 160 participants Est. completion 2007-05 15 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00320489

    Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia

    Not yet reported Eli Lilly and Company 524 participants Est. completion 2009-09 49 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00324051

    Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

    Not yet reported Eli Lilly and Company 284 participants Est. completion 2007-09 8 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00329108

    Ziprasidone And Olanzapine's Outcomes In Mania

    Not yet reported Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 29 participants Est. completion 2008-01 19 sites
    Other conditions: Acute Mania, Bipolar Disorder, Manic
    View official trial listing →
  • Completed NCT NCT00330863

    Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

    Not yet reported Northwell Health 357 participants Est. completion 2011-01 8 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00331825

    Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism

    Not yet reported Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan 70 participants Est. completion 2003-07 1 site
    Other conditions: Schizophrenia, Extrapyramidal Syndrome
    View official trial listing →
  • Completed NCT NCT00337662

    Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

    Not yet reported Eli Lilly and Company 628 participants Est. completion 2007-12 34 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
    View official trial listing →
  • Completed NCT NCT00338949

    Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes

    Not yet reported Veterans Medical Research Foundation 77 participants Est. completion 2009-12 1 site Stand-alone
    Metabolic syndrome Other conditions: Schizophrenia, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT00339079

    Treatment of Hypochondriasis With CBT and/or SSRI

    Not yet reported, Not yet reported Brigham and Women's Hospital 195 participants Est. completion 2011-12 2 sites
    Other conditions: Hypochondriasis
    View official trial listing →
  • Completed NCT NCT00347425

    Switch Study of Existing Atypical Antipsychotics to Bifeprunox

    Not yet reported Solvay Pharmaceuticals 286 participants Est. completion 2008-02 122 sites
    Other conditions: Schizophrenia and Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00351000

    Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

    Not yet reported North Suffolk Mental Health Association 24 participants Est. completion 2007-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00363376

    A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

    Not yet reported Lindner Center of HOPE 42 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00378183

    A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.

    Not yet reported Janssen, LP 120 participants Est. completion 2002-05
    Other conditions: Schizoaffective Disorder, Schizophrenia
    View official trial listing →
  • Completed NCT NCT00380224

    Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.

    Not yet reported Wyeth is now a wholly owned subsidiary of Pfizer 120 participants Est. completion 2007-09 67 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00384332

    Medication, Weight Gain and GI Hormones

    Not yet reported Vanderbilt University 20 participants Est. completion 2010-03 1 site Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00391222

    A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

    Not yet reported Janssen Pharmaceutica N.V., Belgium 585 participants Est. completion 2009-04 63 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00396565

    A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

    Not yet reported Janssen Pharmaceutical K.K. 394 participants Est. completion 2007-11 56 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00399776

    Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

    Creighton University 60 participants Est. completion 2009-09 1 site
    Other conditions: Adolescent Depression
    View official trial listing →
  • Completed NCT NCT00401973

    Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine

    Not yet reported Eli Lilly and Company 199 participants Est. completion 2008-09 15 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorders
    View official trial listing →
  • Completed NCT NCT00402324

    A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients

    Not yet reported Eli Lilly and Company 202 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00418171

    Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

    Not yet reported Pfizer 18239 participants Est. completion 2007-04 5 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00419653

    Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy

    Not yet reported University of Jena 19 participants Est. completion 2007-09
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00423878

    Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

    Not yet reported National Institute of Mental Health (NIMH) 215 participants Est. completion 2010-03 28 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Terminated NCT NCT00428168

    Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment

    Not yet reported OBEcure Ltd. 36 participants Est. completion 2008-12 10 sites
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00433121

    Discontinuation of Antipsychotics and Antidepressants Among Patients With BPSD

    Not yet reported Sykehuset Innlandet HF 24 participants Est. completion 2007-08 1 site Stand-alone
    Other conditions: Dementia
    View official trial listing →
  • Completed NCT NCT00438776

    Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

    Not yet reported Lindner Center of HOPE 42 participants Est. completion 2009-03 1 site
    Other conditions: Pathological Gambling
    View official trial listing →
  • Terminated NCT NCT00439634

    Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

    Not yet reported Sanofi 873 participants Est. completion 2009-09 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT00440843

    Zyprexa and Task Engagement in Schizophrenia

    Not yet reported VA Connecticut Healthcare System Est. completion 2012-06 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00446992

    Diabetes in Neuropsychiatric Disorders

    Not yet reported, Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 30 participants Est. completion 2010-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00455442

    A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain

    Not yet reported Corcept Therapeutics 57 participants Est. completion 2007-07 1 site
    Other conditions: Weight-Gain Prevention
    View official trial listing →
  • Completed NCT NCT00483964

    A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia

    Not yet reported Q.Mundewadi Ayurvedic Research & Charitable Trust 200 participants Est. completion 2007-09 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00485498

    Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics

    Not yet reported Eli Lilly and Company 122 participants Est. completion 2003-12 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00485680

    Olanzapine Versus Comparator in the Treatment of Bipolar Disorder

    Not yet reported Eli Lilly and Company 140 participants Est. completion 2005-06 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00485771

    Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

    Not yet reported Eli Lilly and Company 403 participants Est. completion 2005-01 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00485810

    Examining Rapid Acting Intra-Muscular Olanzapine in Japanese Patients With Schizophrenia

    Not yet reported, Not yet reported Eli Lilly and Company 31 participants Est. completion 2004-11 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00485823

    Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 48 participants Est. completion 2003-09 1 site
    Other conditions: Schizophrenic Disorders
    View official trial listing →
  • Completed NCT NCT00486005

    Weight Gain Management in Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 74 participants Est. completion 2003-10 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00488891

    The Paliperidone ER Observational Study of Economic, Functional, and Clinical Outcomes in Patients With Schizophrenia

    Ortho-McNeil Janssen Scientific Affairs, LLC 43 participants Est. completion 2007-10
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00489593

    Olanzapine in Patients With Advanced Cancer and Weight Loss

    Not yet reported M.D. Anderson Cancer Center 57 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Advanced Cancer, Weight Loss
    View official trial listing →
  • Completed NCT NCT00490971

    A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 768 participants Est. completion 2010-04 78 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00493233

    Antipsychotic Polypharmacy in Schizophrenia

    Not yet reported Centre for Addiction and Mental Health 100 participants 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00509067

    Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

    Not yet reported Georgetown University 43 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00510146

    Olanzapine Treatment of Patients With Bipolar I Disorder

    Not yet reported Eli Lilly and Company 514 participants Est. completion 2010-07 16 sites Stand-alone
    Other conditions: Depression, Bipolar
    View official trial listing →
  • Completed NCT NCT00510211

    An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.

    Eli Lilly and Company 1131 participants Est. completion 2009-05 3 sites
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00512070

    Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

    Not yet reported Seattle Institute for Biomedical and Clinical Research 40 participants Est. completion 2024-12 1 site Stand-alone
    Metabolic syndrome Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity
    View official trial listing →
  • Completed NCT NCT00512291

    Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

    Not yet reported M.D. Anderson Cancer Center 25 participants Est. completion 2009-08 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT00515723

    Glucose and Lipid Metabolism on Antipsychotic Medication

    Not yet reported Washington University School of Medicine 96 participants Est. completion 2008-12 2 sites
    Type 2 diabetes Other conditions: Schizophrenia, Schizoaffective Disorder, Hyperglycemia
    View official trial listing →
  • Completed NCT NCT00520507

    An Investigation of the Sleep Architecture and Consequent Cognitive Changes in Olanzapine-Treated Depressed Patients

    Not yet reported Queen's University 27 participants Est. completion 2009-05 1 site Stand-alone
    Other conditions: Bipolar Disorder, Depression, Depressive Disorder
    View official trial listing →
  • Completed NCT NCT00528359

    β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain 36 participants Est. completion 2007-02 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00534183

    Metabolic Profile and Anthropometric Changes in Schizophrenia

    Not yet reported Central Institute of Psychiatry, Ranchi, India 2006 participants Est. completion 2006-12 1 site Stand-alone
    Metabolic syndrome Other conditions: Diabetes, Obesity
    View official trial listing →
  • Completed NCT NCT00563992

    Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder

    Not yet reported New York State Psychiatric Institute 98 participants Est. completion 2008-10 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00567034

    Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

    Not yet reported Mclean Hospital 30 participants Est. completion 2011-12 1 site
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Withdrawn NCT NCT00568672

    Optimal Duration of Olanzapine Add-on Therapy in Major Depression

    Not yet reported Charite University, Berlin, Germany Est. completion 2008-04 1 site
    Other conditions: Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression
    View official trial listing →
  • Completed NCT NCT00615433

    Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

    Not yet reported Sumitomo Pharma America, Inc. 478 participants Est. completion 2010-01 52 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00618748

    Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

    Not yet reported Eli Lilly and Company 101 participants Est. completion 2010-09 10 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT00625170

    Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans

    Not yet reported Leiden University Medical Center 11 participants Est. completion 2004-12 1 site
    Other conditions: Insulin Resistance, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT00632645

    Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride

    Not yet reported Assistance Publique - Hôpitaux de Paris 180 participants Est. completion 2017-04-28 1 site Stand-alone
    Other conditions: Huntington Disease
    View official trial listing →
  • Completed NCT NCT00636896

    Effects of Modafinil on Olanzapine Weight Gain

    Not yet reported Neuropsychiatric Research Institute, Fargo, North Dakota 50 participants Est. completion 2007-08 1 site Stand-alone
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00640510

    A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 34 participants Est. completion 2008-07 11 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00645099

    A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

    Not yet reported Janssen-Cilag International NV 462 participants Est. completion 2009-04 46 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00647777

    Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

    Not yet reported Mylan Pharmaceuticals Inc 32 participants Est. completion 2003-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00648921

    Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg

    Not yet reported Mylan Pharmaceuticals Inc 30 participants Est. completion 2003-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00650793

    A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 473 participants Est. completion 2006-02
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00654576

    Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia

    Not yet reported Central South University 1400 participants Est. completion 2007-12 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00664976

    Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy

    Not yet reported Norwegian University of Science and Technology 73 participants Est. completion 2013-09 2 sites
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00667745

    Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

    Not yet reported National Institute of Mental Health (NIMH) 283 participants Est. completion 2010-03 6 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Withdrawn NCT NCT00672464

    Cardio Risk of Acute Schizophrenia Olanzapine Duke

    Not yet reported Duke University Est. completion 2010-02 2 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00678457

    Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

    Not yet reported University of Virginia 40 participants Est. completion 2008-05 2 sites Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Completed NCT NCT00682448

    Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

    Not yet reported Rush University Medical Center 25 participants Est. completion 2011-08 1 site
    Other conditions: Metabolic Complications
    View official trial listing →
  • Completed NCT NCT00685334

    Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa

    Not yet reported New York State Psychiatric Institute 22 participants Est. completion 2006-09 2 sites Stand-alone
    Other conditions: Eating Disorders
    View official trial listing →
  • Completed NCT NCT00686998

    Phase IIA Study in Patients With Schizophrenia

    Not yet reported AstraZeneca 106 participants Est. completion 2009-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00690235

    Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

    Not yet reported University of Texas Southwestern Medical Center 33 participants Est. completion 2011-08 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
    View official trial listing →
  • Completed NCT NCT00692185

    Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

    Not yet reported New York State Psychiatric Institute 23 participants Est. completion 2010-09 1 site Stand-alone
    Other conditions: Eating Disorders
    View official trial listing →
  • Completed NCT NCT00699946

    Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

    Not yet reported The New England Baptist Hospital 495 participants Est. completion 2007-10 1 site
    Other conditions: Delirium
    View official trial listing →
  • Terminated NCT NCT00701753

    A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

    TheraGenetics Limited 24 participants Est. completion 2009-03 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00704860

    Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism

    Not yet reported University of Ottawa 27 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Major Depression
    View official trial listing →
  • Completed NCT NCT00712686

    Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 690 participants Est. completion 2003-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00716755

    Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.

    Not yet reported Centre for Addiction and Mental Health 45 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorder
    View official trial listing →
  • Completed NCT NCT00728195

    An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 498 participants Est. completion 2010-02 45 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00734435

    Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

    Not yet reported Orexigen Therapeutics, Inc 26 participants Est. completion 2008-12 9 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
    View official trial listing →
  • Withdrawn NCT NCT00737191

    Opioids With or Without Olanzapine in Treating Patients With Moderate to Severe Cancer Pain

    Not yet reported Mayo Clinic Est. completion 2009-11 Stand-alone
    Other conditions: Hematopoietic/Lymphoid Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00741026

    A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers

    Not yet reported Milton S. Hershey Medical Center 15 participants Est. completion 2011-05 1 site Stand-alone
    Other conditions: Insulin Resistance, Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00746785

    A New Pharmacotherapy for Alcohol Dependence: Olanzapine

    Not yet reported The Mind Research Network 304 participants Est. completion 2011-09 1 site Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Status unknown NCT NCT00752960

    DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

    Genomas, Inc 1000 participants Est. completion 2009-12 2 sites
    Other conditions: Psychoses
    View official trial listing →
  • Completed NCT NCT00759421

    Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

    Not yet reported H. Lundbeck A/S 96 participants Est. completion 2008-04 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00759460

    Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

    Not yet reported H. Lundbeck A/S 250 participants Est. completion 2008-04 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00767715

    A Study in the Treatment of Acute Mania

    Not yet reported Eli Lilly and Company 11 participants Est. completion 2005-04 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT00770744

    Efficacy of Lu 31-130 in Patients With Schizophrenia

    Not yet reported H. Lundbeck A/S 93 participants Est. completion 2009-11 21 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00797277

    Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia

    Not yet reported National Taiwan University Hospital 67 participants Est. completion 2009-06 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, Agitation
    View official trial listing →
  • Completed NCT NCT00802100

    Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

    Not yet reported National Institute of Mental Health (NIMH) 21 participants Est. completion 2009-10 13 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00806234

    Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

    Not yet reported Johns Hopkins University 127 participants Est. completion 2014-03 4 sites
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT00816894

    D-serine Monotherapy for Schizophrenia

    Not yet reported Herzog Hospital 18 participants Est. completion 2013-02 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00827918

    A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

    Not yet reported Merck Sharp & Dohme LLC 216 participants Est. completion 2010-04
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT00833300

    Haloperidol vs Olanzapine for the Management of ICU Delirium

    Not yet reported Richard Hall 200 participants Est. completion 2011-11 2 sites
    Other conditions: Delirium, Agitation
    View official trial listing →
  • Completed NCT NCT00844857

    A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression

    Not yet reported Eli Lilly and Company 291 participants Est. completion 2012-02 7 sites Stand-alone
    Other conditions: Bipolar Depression
    View official trial listing →
  • Completed NCT NCT00845026

    A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

    Not yet reported Denovo Biopharma LLC 261 participants Est. completion 2010-12 23 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00845507

    Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

    Not yet reported University of Cincinnati 54 participants Est. completion 2015-07 1 site
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT00845988

    Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

    Not yet reported Seoul National University Hospital 28 participants Est. completion 2012-03 1 site
    Other conditions: Bipolar Disorders, Metabolic Complication
    View official trial listing →
  • Completed NCT NCT00852956

    Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects

    Not yet reported OBEcure Ltd. 50 participants Est. completion 2009-04 2 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00854919

    Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder

    Not yet reported Osaka City University Est. completion 2007-12 1 site
    Other conditions: SSRI-Refractory Obsessive-Compulsive Disorder
    View official trial listing →
  • Completed NCT NCT00876772

    Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported, Not yet reported Charite University, Berlin, Germany 40 participants Est. completion 2012-07 1 site
    Other conditions: Amyotrophic Lateral Sclerosis (ALS)
    View official trial listing →
  • Terminated NCT NCT00885690

    Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)

    Not yet reported University of Aarhus 11 participants Est. completion 2012-11 2 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT00910780

    Metabolic Effects of Antipsychotic Substitution in Children

    Not yet reported, Not yet reported Washington University School of Medicine Est. completion 2009-11
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT00910988

    Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

    Not yet reported Washington University School of Medicine 46 participants Est. completion 2012-06 1 site
    Other conditions: Hyperglycemia, Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT00918021

    Polypharmacy in Clozapine-resistant Schizophrenia

    Not yet reported Niuvanniemi Hospital 30 participants Est. completion 2010-07 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00926965

    Tardive Dyskinesia and Cognitive Function

    Not yet reported Taipei Veterans General Hospital, Taiwan 80 participants Est. completion 2007-12 1 site Stand-alone
    Other conditions: Tardive Dyskinesia, Neurocognitive Function
    View official trial listing →
  • Completed NCT NCT00932529

    Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting

    Not yet reported University of Bergen 226 participants Est. completion 2010-01 1 site
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Withdrawn NCT NCT00934908

    Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine

    Not yet reported Medical University of South Carolina Est. completion 2009-03 1 site
    Other conditions: Bipolar Disorder, Schizophrenia
    View official trial listing →
  • Completed NCT NCT00937755

    The Study of Atypical Antipsychotics-induced Metabolic Disturbances

    Taipei Medical University Hospital 80 participants Est. completion 2009-05 1 site
    Other conditions: Schizophrenia, Antipsychotics
    View official trial listing →
  • Completed NCT NCT00958568

    A Study in Relapse Prevention of Treatment-Resistant Depression

    Not yet reported Eli Lilly and Company 892 participants Est. completion 2012-03 66 sites Stand-alone
    Other conditions: Treatment Resistant Depression
    View official trial listing →
  • Completed NCT NCT00970281

    A Study of Olanzapine in Patients With Schizophrenia

    Not yet reported Eli Lilly and Company 91 participants Est. completion 2011-04 11 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT00977301

    Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)

    Not yet reported Radboud University Medical Center 24 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT00981526

    Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

    Not yet reported University of Massachusetts, Worcester 66 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT00982020

    Study in Adolescents With Schizophrenia or Bipolar Disorder

    Not yet reported Eli Lilly and Company 203 participants Est. completion 2013-05 14 sites Stand-alone
    Other conditions: Bipolar I Disorder, Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT00988728

    Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

    Not yet reported Merck Sharp & Dohme LLC Est. completion 2012-07
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT01000402

    Juvenile Bipolar Disorder Outpatient Program

    Not yet reported Federal University of Rio Grande do Sul 150 participants Est. completion 2014-11 1 site
    Other conditions: Bipolar Disorder, Attention Deficit Disorder With Hyperactivity
    View official trial listing →
  • Completed NCT NCT01029769

    Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia

    Not yet reported Technical University of Munich 350 participants Est. completion 2015-03 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
    View official trial listing →
  • Completed NCT NCT01043250

    Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

    Samsung Medical Center 81 participants Est. completion 2010-12 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01052103

    A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

    Not yet reported Denovo Biopharma LLC 167 participants Est. completion 2012-06 9 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01052389

    Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia

    Not yet reported Mario Negri Institute for Pharmacological Research 300 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01057329

    Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

    Medical University of Vienna 200 participants Est. completion 2019-03-05 1 site
    Obstructive sleep apnea Other conditions: Depression, ADHD
    View official trial listing →
  • Status unknown NCT NCT01057849

    Standard Comprehensive Intervention to Treat First-episode Schizophrenia

    Not yet reported Peking University 600 participants 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Enrolling by invitation NCT NCT01088386

    Zyprexa® Relprevv™ Patient Care Program

    Eli Lilly and Company 4000 participants Est. completion 2026-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01123408

    Clozapine and Olanzapine Treatment of Aggression

    Not yet reported Nathan Kline Institute for Psychiatric Research 110 participants Est. completion 2004-07 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01129674

    A Long-Term, Open-Label, Study on Schizophrenia

    Not yet reported, Not yet reported Denovo Biopharma LLC 560 participants Est. completion 2012-10 81 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01139463

    Study of Blood Lactate Levels in Patients Treated With Antipsychotics

    University of Split 60 participants Est. completion 2009-10 1 site
    Other conditions: Movement Disorders, Lactic Acidosis
    View official trial listing →
  • Terminated NCT NCT01148264

    Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis

    Not yet reported Karin Jordan 23 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Emesis
    View official trial listing →
  • Completed NCT NCT01149577

    Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients

    Not yet reported Central Institute of Psychiatry, Ranchi, India 25 participants Est. completion 2009-04 1 site Stand-alone
    Other conditions: Schizophrenia, Sleep
    View official trial listing →
  • Completed NCT NCT01160991

    Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

    Not yet reported Central Institute of Mental Health, Mannheim 10 participants Est. completion 2006-10 1 site Stand-alone
    Other conditions: Schizophrenia, Diabetes, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT01164059

    Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

    Not yet reported University of Bremen 149 participants Est. completion 2014-03 18 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01168336

    Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects

    Not yet reported OBEcure Ltd. 90 participants Est. completion 2010-12 2 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01170117

    Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

    Not yet reported New York State Psychiatric Institute 152 participants Est. completion 2017-06 5 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Terminated NCT NCT01184443

    Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents

    Not yet reported Children's Hospital of Eastern Ontario 38 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Eating Disorder
    View official trial listing →
  • Completed NCT NCT01185743

    Antipsychotics and Gene Expression in Soft Tissues

    Not yet reported Medical University of Vienna 16 participants Est. completion 2017-01-01 1 site
    Other conditions: Schizophrenia, Diabetes
    View official trial listing →
  • Withdrawn NCT NCT01193166

    Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

    Not yet reported Ortho-McNeil Janssen Scientific Affairs, LLC Est. completion 2012-09
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01207414

    Switching to Iloperidone From Other Antipsychotics in Schizophrenia

    Not yet reported Novartis 501 participants Est. completion 2012-01 59 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01231074

    Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

    Not yet reported Nationwide Children's Hospital 96 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Obesity, Weight Gain, Psychotropic Induced Weight Gain
    View official trial listing →
  • Completed NCT NCT01234454

    Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

    Not yet reported University of North Carolina, Chapel Hill 34 participants Est. completion 2007-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01234779

    A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

    Not yet reported Hoffmann-La Roche 301 participants Est. completion 2012-09 46 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT01272752

    Anti-psychotic Medication (New Use) Weight Loss Study

    Not yet reported Avera McKennan Hospital & University Health Center Est. completion 2013-12 1 site
    Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT01272765

    Anti-psychotic Medication (Stable Dose) Weight Loss Study

    Not yet reported Avera McKennan Hospital & University Health Center Est. completion 2013-01 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01303601

    Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression

    Not yet reported China Medical University, China 68 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Bipolar Disorder, Depression, Bipolar
    View official trial listing →
  • Terminated NCT NCT01305707

    Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression

    Not yet reported Hospital Universitari de Bellvitge 104 participants Est. completion 2014-07 3 sites
    Other conditions: Depression
    View official trial listing →
  • Completed NCT NCT01323205

    Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia

    Not yet reported Janssen Research & Development, LLC 100 participants Est. completion 2012-12 20 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01342120

    PHARMO Institute Seroquel Safety Study

    AstraZeneca 18325 participants Est. completion 2010-11
    Other conditions: Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
    View official trial listing →
  • Status unknown NCT NCT01389908

    A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

    Not yet reported Shalvata Mental Health Center 2 participants 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorders
    View official trial listing →
  • Terminated NCT NCT01420575

    Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

    Not yet reported VA Nebraska Western Iowa Health Care System 8 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01485692

    Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

    Not yet reported University of Sao Paulo 120 participants Est. completion 2011-03 1 site
    Other conditions: Psychomotor Agitation
    View official trial listing →
  • Terminated NCT NCT01491490

    Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine

    Not yet reported GW Research Ltd 2 participants Est. completion 2012-10 6 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01495741

    Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)

    Organon and Co 42 participants Est. completion 2017-12-18
    Other conditions: Bipolar Disorder, Schizophrenia
    View official trial listing →
  • Completed NCT NCT01496183

    Metabolic Effects of Olanzapine in Healthy Males

    Not yet reported State University of New York at Buffalo 24 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01498770

    An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

    Organon and Co 42 participants Est. completion 2017-12-21
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01503398

    Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions

    Not yet reported Dr. Reddy's Laboratories Limited 48 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Fasting
    View official trial listing →
  • Completed NCT NCT01503424

    Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study

    Not yet reported Dr. Reddy's Laboratories Limited 48 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Fed
    View official trial listing →
  • Completed NCT NCT01503437

    Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition

    Not yet reported Dr. Reddy's Laboratories Limited 22 participants Est. completion 2006-12 1 site Stand-alone
    Other conditions: Fasting
    View official trial listing →
  • Completed NCT NCT01503450

    Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition

    Not yet reported Dr. Reddy's Laboratories Limited 26 participants Est. completion 2006-12 1 site Stand-alone
    Other conditions: Fed
    View official trial listing →
  • Completed NCT NCT01539733

    Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer

    Not yet reported Amsterdam UMC, location VUmc 101 participants Est. completion 2017-04 2 sites Stand-alone
    Other conditions: Delirium, Advanced Cancer
    View official trial listing →
  • Withdrawn NCT NCT01567124

    Alleviating the Metabolic Side Effects of Antipsychotic Medications

    Not yet reported Baker Heart and Diabetes Institute 4 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01592201

    A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug

    Not yet reported Janssen Korea, Ltd., Korea 13 participants Est. completion 2013-06 9 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01593774

    Melatonin for Prevention of Metabolic Side Effects of Olanzapine

    Not yet reported Guilan University of Medical Sciences 36 participants Est. completion 2013-03 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01607762

    A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics

    Not yet reported Janssen Research & Development, LLC 31 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01609153

    Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

    Not yet reported Heinrich-Heine University, Duesseldorf 328 participants Est. completion 2019-04 21 sites
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT01617187

    A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)

    Not yet reported Organon and Co 360 participants Est. completion 2014-09-09 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01617200

    Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

    Not yet reported Forest Laboratories 105 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT01625923

    A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis

    Not yet reported University of Michigan 3 participants Est. completion 2019-06 2 sites Stand-alone
    Other conditions: Idiopathic Gastroparesis
    View official trial listing →
  • Completed NCT NCT01686815

    Cross-Sectional Iloperidone IVGTT

    Massachusetts General Hospital 37 participants Est. completion 2016-05 1 site
    Metabolic syndrome Other conditions: Schizophrenia, Serious Mental Illness, Insulin Resistance, Glucose Metabolism
    View official trial listing →
  • Status unknown NCT NCT01765829

    Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

    Not yet reported Fundación Pública Andaluza Progreso y Salud 104 participants Est. completion 2015-11 17 sites
    Other conditions: Psychosis Nos/Other
    View official trial listing →
  • Completed NCT NCT01786369

    Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.

    Northwell Health 106 participants Est. completion 2015-04 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01833897

    NMDA Antagonists in Bipolar Depression

    Not yet reported New York State Psychiatric Institute 8 participants Est. completion 2016-03 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT01864551

    Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder

    Not yet reported Tri-Service General Hospital (TSGH) 60 participants Est. completion 2012-09 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Status unknown NCT NCT01893229

    Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania

    Not yet reported Guiyun Xu 120 participants Est. completion 2015-12 2 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Terminated NCT NCT01894984

    An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

    Xian-Janssen Pharmaceutical Ltd. 640 participants Est. completion 2009-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01903837

    A Study of ALKS 3831 in Adults With Schizophrenia

    Not yet reported Alkermes, Inc. 347 participants Est. completion 2015-03 61 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT01920802

    Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

    Not yet reported New York State Psychiatric Institute 31 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01977300

    Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

    Not yet reported University of British Columbia 159 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT01990755

    Neurobiology of Eating Disorders Treatments

    Not yet reported University of Turin, Italy 112 participants Est. completion 2013-05 1 site
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT01996488

    Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition

    Not yet reported Torrent Pharmaceuticals Limited 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01996501

    Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition

    Not yet reported Torrent Pharmaceuticals Limited 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02006862

    eVAluatIon of OLanzapine TreatmEnT

    Elpen Pharmaceutical Co. Inc. 468 participants Est. completion 2014-12 1 site
    Other conditions: Bipolar Disorder, Schizophrenia
    View official trial listing →
  • Completed NCT NCT02007928

    Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic

    Not yet reported Centre Hospitalier Universitaire de Nice 200 participants Est. completion 2017-07 14 sites
    Other conditions: Dissociative Disorders, Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02040883

    Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia

    Not yet reported Qingyun Yin 100 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02051387

    Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

    Not yet reported Central Institute of Mental Health, Mannheim 74 participants Est. completion 2017-08 2 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02087579

    Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

    Not yet reported Janssen Research & Development, LLC 305 participants Est. completion 2014-12 24 sites Stand-alone
    Other conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
    View official trial listing →
  • Terminated NCT NCT02088060

    A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

    Not yet reported Central Institute of Mental Health, Mannheim 150 participants Est. completion 2024-09-16 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02093858

    The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

    Central South University 212 participants Est. completion 2017-12 1 site
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02097823

    Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy

    Not yet reported Indiana University 15 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Chemotherapy Induced Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT02116530

    Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

    Not yet reported Alliance for Clinical Trials in Oncology 401 participants Est. completion 2017-06-15 177 sites Stand-alone
    Other conditions: Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT02129478

    Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study

    Not yet reported The Hospital for Sick Children 15 participants Est. completion 2016-01 3 sites Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT02137616

    Antipsychotic to Treat Psychosis Syndrome

    Not yet reported Central South University 300 participants Est. completion 2014-12 1 site
    Other conditions: Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT02137993

    Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia

    Not yet reported HK inno.N Corporation 64 participants Est. completion 2013-05
    Other conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT02161718

    A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

    Not yet reported Alkermes, Inc. 300 participants Est. completion 2017-02-01 71 sites Stand-alone
    Alcohol use disorder Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02181803

    Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

    Not yet reported Merck Sharp & Dohme LLC 55 participants Est. completion 2015-04-23 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02192723

    A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

    Not yet reported Beijing HuiLongGuan Hospital 550 participants Est. completion 2014-06 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT02213887

    Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications

    Not yet reported University of British Columbia Est. completion 2020-11-02 1 site
    Other conditions: Psychotic Disorders, Gastroesophageal Reflux
    View official trial listing →
  • Completed NCT NCT02237417

    Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

    Not yet reported University of Utah 47 participants Est. completion 2020-07-30 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02248987

    Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia

    Seoul National University Hospital 36 participants Est. completion 2016-05 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02282085

    Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia

    Not yet reported Matt Byerly 200 participants 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02287259

    Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)

    Not yet reported Tadashi Hasegawa 50 participants Est. completion 2019-03-31 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Status unknown NCT NCT02290470

    Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel

    Not yet reported Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 81 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: Nausea, Vomiting
    View official trial listing →
  • Completed NCT NCT02307396

    Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

    Not yet reported Technical University of Munich 21 participants Est. completion 2016-06-22 1 site Stand-alone
    Other conditions: Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
    View official trial listing →
  • Terminated NCT NCT02374567

    Pharmacovigilance in Gerontopsychiatric Patients

    Not yet reported Hannover Medical School 407 participants Est. completion 2017-06-28 5 sites Stand-alone
    Other conditions: Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
    View official trial listing →
  • Terminated NCT NCT02380118

    IM Olanzapine Versus Haloperidol or Midazolam

    Not yet reported The University of Hong Kong 167 participants Est. completion 2019-09 6 sites Stand-alone
    Other conditions: Acute Agitation, Behavioural Emergency
    View official trial listing →
  • Completed NCT NCT02431702

    A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

    Not yet reported Janssen Scientific Affairs, LLC 337 participants Est. completion 2019-11-12 38 sites
    Other conditions: Schizophrenia, Psychotic Disorders
    View official trial listing →
  • Terminated NCT NCT02435095

    Antipsychotic Induced Structural and Functional Brain Changes

    Not yet reported RWTH Aachen University 174 participants Est. completion 2020-08 11 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02435654

    5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia

    Not yet reported Kunming Medical University 128 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: Early-onset Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02439099

    Retinoic Acid Homeostasis in Neuropsychiatric Diseases

    Charite University, Berlin, Germany 200 participants Est. completion 2022-12 1 site
    Other conditions: Major Depression, Alzheimer's Disease, Alcoholism, Schizophrenia
    View official trial listing →
  • Completed NCT NCT02447835

    Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction

    Not yet reported Michael Rickels 15 participants Est. completion 2014-12 1 site
    Other conditions: Normal Non-fluency
    View official trial listing →
  • Terminated NCT NCT02462473

    A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

    Not yet reported Janssen Research & Development, LLC 9 participants Est. completion 2016-01 3 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Status unknown NCT NCT02529163

    Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms

    Not yet reported Centre for Addiction and Mental Health 24 participants Est. completion 2019-07 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT02536846

    The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

    Not yet reported Dost Ongur 35 participants Est. completion 2019-11-08 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Withdrawn NCT NCT02538081

    Nicotinic Receptors and Schizophrenia

    Not yet reported, Not yet reported VA Office of Research and Development Est. completion 2016-08 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02562287

    Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder

    Not yet reported Hospital de Clinicas de Porto Alegre 54 participants Est. completion 2020-12 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02600741

    Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

    Janssen Scientific Affairs, LLC 296 participants Est. completion 2018-07-05 34 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02634346

    A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

    Not yet reported Alkermes, Inc. 403 participants Est. completion 2017-06-07 31 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02634463

    Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

    Not yet reported Janssen Research & Development, LLC 81 participants Est. completion 2016-11-09 1 site
    Other conditions: Immunoassay, Antipsychotic
    View official trial listing →
  • Completed NCT NCT02635984

    Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens

    Not yet reported Augusta University 108 participants Est. completion 2017-12 1 site
    Other conditions: Complications of Bone Marrow Transplant, Hematologic Neoplasms
    View official trial listing →
  • Completed NCT NCT02643355

    Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED

    Not yet reported Hennepin Healthcare Research Institute 70 participants Est. completion 2017-06-21 1 site Stand-alone
    Other conditions: Substance Withdrawal Syndrome
    View official trial listing →
  • Completed NCT NCT02669758

    A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

    Not yet reported Alkermes, Inc. 281 participants Est. completion 2018-06-29 31 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02694328

    A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

    Not yet reported Alkermes, Inc. 561 participants Est. completion 2018-11-07 54 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02708394

    Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

    Not yet reported Wayne State University 31 participants Est. completion 2023-10-01 1 site Stand-alone
    Other conditions: Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
    View official trial listing →
  • Completed NCT NCT02717195

    Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

    Not yet reported H. Lundbeck A/S 1098 participants Est. completion 2018-10-08 147 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02755116

    Olanzapine for Nausea After Surgery

    Not yet reported Jaime B Hyman 180 participants Est. completion 2019-09-05 1 site Stand-alone
    Other conditions: Postoperative Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT02804568

    A Phase 1 Safety Study in Adults With Schizophrenia

    Not yet reported Alkermes, Inc. 42 participants Est. completion 2016-08 3 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02850445

    Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients

    Not yet reported Guangzhou Psychiatric Hospital 170 participants 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02861859

    Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study

    Not yet reported Ottawa Hospital Research Institute 221 participants Est. completion 2019-12-23 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02873208

    A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

    Not yet reported Alkermes, Inc. 266 participants Est. completion 2019-10-17 45 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT02893371

    Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

    University of New Mexico 1037352 participants Est. completion 2019-06-30 1 site
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT02918825

    Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

    Not yet reported Beijing HuiLongGuan Hospital 100 participants Est. completion 2017-09-30 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT02922426

    An Insulin Sensitivity Study in Healthy Subjects

    Not yet reported Alkermes, Inc. 60 participants Est. completion 2017-07-20 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02939287

    Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

    Not yet reported Rush University Medical Center 52 participants Est. completion 2022-12-01 1 site Stand-alone
    Other conditions: Nausea, Vomiting
    View official trial listing →
  • Completed NCT NCT02958800

    Deprescribing Antipsychotics in Long-Term Care

    Not yet reported McMaster University 6 participants Est. completion 2019-08 1 site
    Other conditions: Dementia, Behavior
    View official trial listing →
  • Status unknown NCT NCT02964923

    Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia

    Xijing Hospital 300 participants Est. completion 2017-12 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT02970643

    Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

    Not yet reported Hee Jun Kim 48 participants Est. completion 2017-12 Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT03007303

    The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients

    Dalian Seventh People's Hospital 30 participants Est. completion 2020-07 1 site
    Other conditions: Schizophrenia, Micrognathia
    View official trial listing →
  • Completed NCT NCT03019887

    Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

    Not yet reported Juntendo University 139 participants Est. completion 2017-01 Stand-alone
    Other conditions: Schizophrenia Relapse
    View official trial listing →
  • Completed NCT NCT03030417

    Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

    Not yet reported National Cancer Institute (NCI) 36 participants Est. completion 2023-10-12 2 sites Stand-alone
    Other conditions: Solid Tumors, Lymphoma
    View official trial listing →
  • Completed NCT NCT03066622

    Olanzapine for Acute Headaches

    Not yet reported HealthPartners Institute 122 participants Est. completion 2018-05-20 1 site Stand-alone
    Other conditions: Headache
    View official trial listing →
  • Completed NCT NCT03079219

    Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients

    Not yet reported CCTU 120 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03118986

    RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

    Not yet reported The Hospital for Sick Children 161 participants Est. completion 2026-06-12 9 sites
    Other conditions: Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
    View official trial listing →
  • Completed NCT NCT03137121

    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

    Not yet reported, Not yet reported University of Alabama at Birmingham 30 participants Est. completion 2020-09-15 5 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT03187769

    Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder

    Not yet reported Alkermes, Inc. 426 participants Est. completion 2022-01-03 57 sites Stand-alone
    Other conditions: Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT03211897

    Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation

    Hennepin Healthcare Research Institute 737 participants Est. completion 2017-10-01 1 site
    Other conditions: Agitation,Psychomotor
    View official trial listing →
  • Completed NCT NCT03216941

    Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward

    Not yet reported Universidad Nacional de Rosario 500 participants Est. completion 2016-01-31 1 site
    Other conditions: Psychomotor Agitation, Psychiatric Disorder, Emergency Psychiatric, Tranquilizers
    View official trial listing →
  • Completed NCT NCT03219710

    "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"

    Not yet reported All India Institute of Medical Sciences 240 participants Est. completion 2019-07-31 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Terminated NCT NCT03230864

    Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

    Not yet reported H. Lundbeck A/S 119 participants Est. completion 2019-02-05 41 sites Stand-alone
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Terminated NCT NCT03246620

    Oral Olanzapine Versus Haloperidol or Diazepam

    Not yet reported The University of Hong Kong 12 participants Est. completion 2018-06-01 1 site Stand-alone
    Other conditions: Acute Agitation, Behavioural Emergency
    View official trial listing →
  • Completed NCT NCT03304457

    Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 100 participants Est. completion 2018-03-25 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03319953

    A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

    Not yet reported Neurocrine Biosciences 23 participants Est. completion 2019-11-06 1 site Stand-alone
    Other conditions: Stable Schizophrenia
    View official trial listing →
  • Completed NCT NCT03367572

    Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

    Not yet reported University of Rochester NCORP Research Base 1363 participants Est. completion 2024-04-13 18 sites Stand-alone
    Other conditions: Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT03451734

    Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients

    Central South University 2000 participants Est. completion 2021-06-30 1 site
    Metabolic syndrome Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03478605

    Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis

    Not yet reported Blokhin's Russian Cancer Research Center 130 participants Est. completion 2019-06-01 1 site Stand-alone
    Other conditions: Emesis, Vomiting, Nausea Post Chemotherapy, Nausea, Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT03557931

    A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

    Not yet reported Astellas Pharma Global Development, Inc. 233 participants Est. completion 2019-10-21 27 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03565068

    A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

    Not yet reported Merck Sharp & Dohme LLC 75 participants Est. completion 2020-04-03 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT03568500

    A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 44 participants Est. completion 2019-09-06 5 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
    View official trial listing →
  • Status unknown NCT NCT03571126

    Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer

    Not yet reported Zunyi Medical College 156 participants Est. completion 2023-08-01 2 sites Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting, Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT03575637

    Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

    Not yet reported Peking University 180 participants Est. completion 2021-06 1 site Stand-alone
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT03578081

    Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

    Not yet reported Alliance for Clinical Trials in Oncology 690 participants Est. completion 2023-05-01 566 sites Stand-alone
    Other conditions: Malignant Neoplasm
    View official trial listing →
  • Completed NCT NCT03624322

    Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

    Not yet reported Impel Pharmaceuticals 38 participants Est. completion 2018-10-03 1 site Stand-alone
    Other conditions: Acute Agitation
    View official trial listing →
  • Completed NCT NCT03631004

    Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients

    Not yet reported, Not yet reported Instituto do Cancer do Estado de São Paulo 100 participants Est. completion 2021-02-10 1 site Stand-alone
    Other conditions: Postoperative Nausea, Postoperative Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT03651674

    Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study

    Not yet reported Xidian University 200 participants Est. completion 2020-04-01
    Other conditions: Schizophrenia, Bipolar Disorder
    View official trial listing →
  • Completed NCT NCT03666715

    A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

    Janssen-Cilag Farmaceutica Ltda. 55 participants Est. completion 2021-05-31 1 site
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03679182

    Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care

    Not yet reported Khon Kaen University 15 participants Est. completion 2021-09 1 site Stand-alone
    Other conditions: Nausea, Vomiting, End Stage Cancer
    View official trial listing →
  • Completed NCT NCT03730857

    Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics

    Not yet reported Calo Psychiatric Center 111 participants Est. completion 2008-12
    Other conditions: Schizophrenia
    View official trial listing →
  • Active, not recruiting NCT NCT03741478

    Intranasal Insulin and Olanzapine Study in Healthy Volunteers

    Not yet reported Centre for Addiction and Mental Health 64 participants Est. completion 2026-07-30 2 sites Stand-alone
    Other conditions: Healthy Controls
    View official trial listing →
  • Active, not recruiting NCT NCT03781115

    Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

    Not yet reported University of Arizona 24 participants Est. completion 2027-02-10 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT03790085

    Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

    Not yet reported Tianjin Medical University General Hospital 2700 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Schizophrenia, Major Depressive Disorder, Anxiety Disorders
    View official trial listing →
  • Completed NCT NCT03818256

    A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

    Not yet reported Corcept Therapeutics 71 participants Est. completion 2022-07-06 27 sites
    Other conditions: Antipsychotic-induced Weight Gain (AIWG)
    View official trial listing →
  • Status unknown NCT NCT03857581

    Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder

    Not yet reported Augusta University 100 participants Est. completion 2021-07 1 site Stand-alone
    Substance use disorder Other conditions: Psychosis
    View official trial listing →
  • Status unknown NCT NCT03876938

    Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

    Not yet reported Mahidol University 147 participants Est. completion 2020-12 2 sites Stand-alone
    Other conditions: Antiemetic for Highly Emetogenic Chemotherapy
    View official trial listing →
  • Completed NCT NCT03877562

    The Effect of CORT118335 on Olanzapine-Induced Weight Gain

    Not yet reported Corcept Therapeutics 96 participants Est. completion 2020-03-25 1 site Stand-alone
    Other conditions: Antipsychotic-induced Weight Gain
    View official trial listing →
  • Terminated NCT NCT03899506

    Olanzapine Versus Midazolam for Agitation

    Hennepin Healthcare Research Institute 206 participants Est. completion 2018-07-16 1 site
    Other conditions: Agitation,Psychomotor
    View official trial listing →
  • Withdrawn NCT NCT03960151

    Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

    Not yet reported Costantine Albany Est. completion 2022-03 Stand-alone
    Other conditions: Germ Cell Tumor
    View official trial listing →
  • Completed NCT NCT04002258

    Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment

    Shanghai Mental Health Center 10363 participants Est. completion 2022-10-25 1 site
    Other conditions: Schizophrenia, Antipyretics Toxicity, Prolactin Excess
    View official trial listing →
  • Completed NCT NCT04002700

    A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

    Janssen Research & Development, LLC 1234412 participants Est. completion 2019-05-31 1 site
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT04076371

    The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

    Not yet reported Beijing HuiLongGuan Hospital 1640 participants Est. completion 2018-12 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT04181385

    Acute Olanzapine and Lipid Response

    Not yet reported, Not yet reported University Health Network, Toronto 15 participants Est. completion 2020-06-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT04216329

    Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2028-07-30 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Newly Diagnosed, Glioblastoma
    View official trial listing →
  • Completed NCT NCT04218981

    Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders

    Not yet reported Central South University 200 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Common Mental Disorder
    View official trial listing →
  • Completed NCT NCT04232423

    Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

    Not yet reported Department of Medical Services Ministry of Public Health of Thailand 90 participants Est. completion 2021-09-30 1 site Stand-alone
    Other conditions: Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
    View official trial listing →
  • Completed NCT NCT04312503

    Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"

    Aziende Chimiche Riunite Angelini Francesco S.p.A 95 participants Est. completion 2022-10-31 18 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT04437017

    Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

    Not yet reported Fifth Affiliated Hospital, Sun Yat-Sen University 557 participants Est. completion 2022-07-01 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT04478526

    Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions

    Not yet reported Dr. Nazanin Alavi 115 participants Est. completion 2021-05-01 1 site Stand-alone
    Other conditions: Generalized Anxiety Disorder
    View official trial listing →
  • Terminated NCT NCT04503668

    Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients

    Not yet reported University of Michigan Rogel Cancer Center 62 participants Est. completion 2024-03-11 1 site Stand-alone
    Other conditions: Gynecologic Cancer
    View official trial listing →
  • Suspended NCT NCT04518319

    Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome

    Not yet reported Shanghai Mental Health Center 120 participants Est. completion 2024-11 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT04524403

    A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

    Not yet reported Corcept Therapeutics 150 participants Est. completion 2022-08-25 40 sites
    Other conditions: Antipsychotic-induced Weight Gain (AIWG)
    View official trial listing →
  • Status unknown NCT NCT04529226

    Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    Not yet reported Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 75 participants Est. completion 2025-12-30 20 sites
    Other conditions: Psychosis, Intellectual Disability
    View official trial listing →
  • Completed NCT NCT04535141

    Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

    Not yet reported UNC Lineberger Comprehensive Cancer Center 91 participants Est. completion 2022-04-11 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT04536558

    Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

    Not yet reported Sun Yat-sen University 352 participants Est. completion 2021-03-30 18 sites Stand-alone
    Other conditions: Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
    View official trial listing →
  • Completed NCT NCT04669132

    Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

    Not yet reported Instituto Brasileiro de Controle do Cancer 50 participants Est. completion 2022-01-17 1 site Stand-alone
    Other conditions: Nausea Post Chemotherapy
    View official trial listing →
  • Completed NCT NCT04718727

    Olanzapine for the Prevention of Postoperative Nausea and Vomiting

    Not yet reported, Not yet reported Amani Hassan Abdel-Wahab 132 participants Est. completion 2023-02-01 2 sites
    Other conditions: Postoperative Nausea
    View official trial listing →
  • Status unknown NCT NCT04750395

    Comparing Haloperidol and Olanzapine in Treating Terminal Delirium

    Not yet reported HCA Hospice Care 80 participants Est. completion 2024-05 1 site Stand-alone
    Other conditions: Delirium, Terminal Illness
    View official trial listing →
  • Status unknown NCT NCT04833023

    HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

    Not yet reported Tan Tock Seng Hospital 72 participants Est. completion 2024-12 3 sites
    Other conditions: Haloperidol, Advanced Cancer, Hyperactive Delirium, Olanzapine, End-stage Organ Disease
    View official trial listing →
  • Completed NCT NCT04876521

    Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression

    Not yet reported All India Institute of Medical Sciences, Bhubaneswar 60 participants Est. completion 2021-06-30 1 site
    Other conditions: Post-Schizophrenic Depression
    View official trial listing →
  • Active, not recruiting NCT NCT04892199

    Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

    Not yet reported Anders Fink-Jensen, MD, DMSci 104 participants Est. completion 2026-08-01 3 sites
    Type 2 diabetes Other conditions: Metabolic Disturbance, Schizophrenia, Clozapine, GLP-1, Olanzapine
    View official trial listing →
  • Completed NCT NCT04898270

    Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients

    Not yet reported Taichung Veterans General Hospital 30 participants Est. completion 2021-04-20 1 site Stand-alone
    Metabolic syndrome Other conditions: Schizophrenia; Psychosis, Flupentixol, Antipsychotic Agents, Central Nervous System Diseases, Clinical Therapy, Olanzapine, Quetiapine
    View official trial listing →
  • Active, not recruiting NCT NCT04939090

    Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

    Not yet reported Alliance for Clinical Trials in Oncology 227 participants Est. completion 2026-12-31 293 sites Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT04987658

    Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

    Not yet reported Alkermes, Inc. 7 participants Est. completion 2023-08-11 2 sites Stand-alone
    Other conditions: Bipolar I Disorder
    View official trial listing →
  • Completed NCT NCT05123976

    Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.

    Not yet reported Joint Stock Company "Farmak" 32 participants Est. completion 2020-11-30 1 site Stand-alone
    Other conditions: Pharmacokinetics
    View official trial listing →
  • Terminated NCT NCT05163717

    INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

    Not yet reported Impel Pharmaceuticals 8 participants Est. completion 2023-04-24 2 sites Stand-alone
    Other conditions: Agitation in Adolescents and Young Adults With ASD
    View official trial listing →
  • Enrolling by invitation NCT NCT05170919

    Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

    Not yet reported Englewood Hospital and Medical Center 170 participants Est. completion 2026-12 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Withdrawn NCT NCT05179772

    Olanzapine in OUD Patients

    Not yet reported University of Pennsylvania Est. completion 2023-01-30 2 sites Stand-alone
    Substance use disorder
    View official trial listing →
  • Status unknown NCT NCT05202275

    The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

    Not yet reported Chinese Academy of Medical Sciences 43 participants Est. completion 2023-09 1 site Stand-alone
    Other conditions: Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect
    View official trial listing →
  • Terminated NCT NCT05213143

    The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

    Not yet reported Marubeni Pharmaceuticals (Suzhou) Co., Ltd. 13 participants Est. completion 2022-11-18 1 site Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT05242874

    Anti-emetic Prophylaxis With or Without Dexamethasone

    Not yet reported Henan Cancer Hospital 442 participants Est. completion 2023-08-15 2 sites Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT05243251

    Olanzapine Anorexia Cachexia

    Not yet reported Cairo University 164 participants Est. completion 2022-12-14 1 site
    Other conditions: Anorexia
    View official trial listing →
  • Status unknown NCT NCT05244577

    Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

    Not yet reported Shi Yanxia 75 participants Est. completion 2024-03-31 1 site Stand-alone
    Other conditions: Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
    View official trial listing →
  • Completed NCT NCT05402111

    A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 31 participants Est. completion 2023-09-27 7 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Withdrawn NCT NCT05403580

    Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

    Not yet reported Mayo Clinic Est. completion 2024-12 Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT05547100

    Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan

    Not yet reported Alkermes, Inc. 12 participants Est. completion 2022-11-19 1 site Stand-alone
    Other conditions: Focus of Study is on Healthy Lactating Women
    View official trial listing →
  • Terminated NCT NCT05590923

    Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

    Not yet reported The Guthrie Clinic 23 participants Est. completion 2025-07-08 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT05600790

    Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress

    Not yet reported Peking University 300 participants Est. completion 2023-02-28 1 site
    Other conditions: Emotional Distress
    View official trial listing →
  • Status unknown NCT NCT05606224

    The Effects and Mechanisms of Mindfulness Intervention for Emotional Distress

    Not yet reported Peking University 200 participants Est. completion 2023-08-30 4 sites
    Other conditions: Emotional Disorder
    View official trial listing →
  • Status unknown NCT NCT05646264

    A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia

    Not yet reported Shanghai Mental Health Center 220 participants Est. completion 2023-08-01 1 site Stand-alone
    Other conditions: Schizophrenia, Negative Symptoms in Schizophrenia
    View official trial listing →
  • Completed NCT NCT05676294

    The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

    Not yet reported Yale University 398 participants Est. completion 2025-12-06 1 site Stand-alone
    Other conditions: Postoperative Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT05693935

    A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 675 participants Est. completion 2025-01-27 82 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Terminated NCT NCT05741502

    An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

    Not yet reported Ohio State University 5 participants Est. completion 2026-01-23 1 site
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT05803642

    A Study of Olanzapine in Patients With Acute Agitation

    Not yet reported Qilu Pharmaceutical Co., Ltd. 318 participants Est. completion 2024-07-02 Stand-alone
    Other conditions: Acute Agitation
    View official trial listing →
  • Completed NCT NCT05805800

    Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV

    Not yet reported Xingchen Peng 275 participants Est. completion 2024-05-15 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting
    View official trial listing →
  • Status unknown NCT NCT05833399

    Correlation of Genetic Variations With Clinical Response in Substance Use Disorder

    Alexandria University 200 participants Est. completion 2024-12 1 site
    Substance use disorder Other conditions: Substance Dependence
    View official trial listing →
  • Completed NCT NCT05857566

    Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

    Not yet reported Response Pharmaceuticals 24 participants Est. completion 2023-09-13 1 site
    Other conditions: Drug-induced Weight Gain
    View official trial listing →
  • Status unknown NCT NCT05889234

    Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study

    First Affiliated Hospital of Chongqing Medical University 180 participants Est. completion 2026-01-01 1 site
    Other conditions: Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy
    View official trial listing →
  • Status unknown NCT NCT05891015

    The Mechanism of Mindfulness Intervention to Alleviate Emotional Distress in Patients With Emotional Disorders

    Not yet reported Peking University 200 participants Est. completion 2025-12-15 1 site
    Other conditions: Emotional Distress, Emotional Disorder
    View official trial listing →
  • Completed NCT NCT05964647

    Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

    Not yet reported University Hospital, Basel, Switzerland 20 participants Est. completion 2025-06-30 1 site
    Other conditions: Healthy
    View official trial listing →
  • Status unknown NCT NCT06035003

    Mechanism of Mindfulness-Based Online Intervention in Enhancing Cognitive Flexibility

    Not yet reported Peking University 595 participants Est. completion 2024-02-28 1 site
    Other conditions: Emotional Distress
    View official trial listing →
  • Completed NCT NCT06040944

    Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients

    Fayoum University 64 participants Est. completion 2022-11-01 1 site
    Other conditions: Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases
    View official trial listing →
  • Status unknown NCT NCT06065722

    Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

    Not yet reported Simon Williamson Clinic 100 participants Est. completion 2023-12-31 1 site
    Other conditions: Chemotherapy Induced Nausea and Vomiting
    View official trial listing →
  • Completed NCT NCT06107803

    A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

    Not yet reported Minerva Neurosciences 17 participants Est. completion 2024-01-12 3 sites Stand-alone
    Other conditions: Negative Symptoms in Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT06128408

    The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset

    Peking University 300 participants Est. completion 2024-10-13
    Other conditions: Treatment-resistant Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT06159322

    Characterizing Response to Antipsychotics in Schizophrenia

    The Royal Ottawa Mental Health Centre 40 participants Est. completion 2024-01-30 1 site
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT06175273

    Pediatric Oncology Nutrition Intervention Trial

    Not yet reported, Not yet reported Corey Hawes 19 participants Est. completion 2025-08-04 1 site Stand-alone
    Other conditions: Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
    View official trial listing →
  • Active, not recruiting NCT NCT06200181

    Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

    Not yet reported M.D. Anderson Cancer Center 69 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Misuse, Opioid
    View official trial listing →
  • Completed NCT NCT06200584

    Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

    Not yet reported Dr Rabia Arshad 140 participants Est. completion 2021-06-10 1 site Stand-alone
    Other conditions: Antipsychotics and Neuroleptics Toxicity
    View official trial listing →
  • Active, not recruiting NCT NCT06251635

    Effects of Antipsychotics on Brain Insulin Action in Females

    Not yet reported Centre for Addiction and Mental Health 15 participants Est. completion 2026-12-31 1 site Stand-alone
    Type 2 diabetes Other conditions: Insulin Resistance, Menstrual Cycle, Antipsychotics
    View official trial listing →
  • Completed NCT NCT06253546

    Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 24 participants Est. completion 2025-06-12 6 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Status unknown NCT NCT06288854

    Efficacy of Olanzapine on Weight Gain in Advanced Gynecologic Cancer with Paclitaxel and Carboplatin: a Double Blind, Placebo-controlled Randomized Trial

    Not yet reported Department of Medical Services Ministry of Public Health of Thailand 48 participants Est. completion 2025-06-30 1 site Stand-alone
    Other conditions: Weight Gain
    View official trial listing →
  • Completed NCT NCT06315283

    An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 153 participants Est. completion 2025-09-04 9 sites
    Other conditions: Schizophrenia
    View official trial listing →
  • Completed NCT NCT06319170

    Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 106 participants Est. completion 2025-01-20 5 sites Stand-alone
    Other conditions: Schizophrenia, Schizoaffective Disorder
    View official trial listing →
  • Completed NCT NCT06331520

    NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

    Not yet reported Fudan University 644 participants Est. completion 2025-08-30 1 site Stand-alone
    Other conditions: Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy
    View official trial listing →
  • Completed NCT NCT06357104

    Detoxification From the Lipid Tract

    Not yet reported Pachankis, Yang I., M.D. 1 participants Est. completion 2024-03-20 1 site Stand-alone
    Other conditions: COVID-19 Vaccine Adverse Reaction
    View official trial listing →
  • Completed NCT NCT06600477

    A Study of Olanzapine After Intranasal and Intramuscular Administration

    Not yet reported Neurelis, Inc. 24 participants Est. completion 2023-11-01 1 site
    Other conditions: Healthy
    View official trial listing →
  • Not yet recruiting NCT NCT06649214

    A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia

    Not yet reported Qilu Pharmaceutical Co., Ltd. 654 participants Est. completion 2026-05 Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Active, not recruiting NCT NCT06754163

    Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients

    Not yet reported St Andrew's Healthcare 20 participants Est. completion 2027-12-30 1 site Added to GLP-1
    Other conditions: Obesity and Obesity-related Medical Conditions, Psychiatric Disorders
    View official trial listing →
  • Terminated NCT NCT06949657

    Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and

    Not yet reported Third People's Hospital, Huzhou City, Zhejiang Province, China 78 participants Est. completion 2024-09-19 1 site
    Other conditions: Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy
    View official trial listing →
  • Not yet recruiting NCT NCT07035821

    Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy

    Not yet reported Shanghai Children's Medical Center 100 participants Est. completion 2026-07-30 1 site Stand-alone
    Other conditions: Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07152184

    Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach

    Not yet reported University Hospital, Strasbourg, France 288 participants Est. completion 2032-02-01 Stand-alone
    Other conditions: Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
    View official trial listing →
  • Completed NCT NCT07190482

    Treatment of Tinnitus With Olanzapine

    Not yet reported University of Sao Paulo 50 participants Est. completion 2025-01-20 1 site
    Other conditions: Tinnitus, Tinnitus, Subjective
    View official trial listing →
  • Completed NCT NCT07403370

    Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

    Shandong Cancer Hospital and Institute 2493 participants Est. completion 2026-03-30 1 site
    Other conditions: Solid Tumours, Olanzapine, Nausea and Vomiting
    View official trial listing →
  • Not yet recruiting NCT NCT07442890

    A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

    Not yet reported Henan Cancer Hospital 238 participants Est. completion 2028-06-30 Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07570875

    Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area

    Not yet reported University of Alabama at Birmingham 100 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Not yet recruiting NCT NCT07722806

    A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors

    Not yet reported Kantonsspital Winterthur KSW 130 participants Est. completion 2028-12 1 site
    Other conditions: Cancer, Advanced Solid Tumors, Malnutrition
    View official trial listing →
  • Available NCT NCT07744113

    An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

    Alkermes, Inc. 1 site
    Other conditions: Bipolar 1 Disorder, Schizophrenia Disorder
    View official trial listing →
  • Enrolling by invitation NCT NCT07747194

    Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant

    Not yet reported Xiao Wang 80 participants Est. completion 2027-12-30 1 site
    Other conditions: Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
    View official trial listing →
  • Completed NCT NCT07834112

    Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder

    Dong-Wook Kim 155 participants Est. completion 2025-12-31 1 site
    Other conditions: Bipolar Disorder (BD)
    View official trial listing →
  • Active, not recruiting NCT NCT07841210

    Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 60 participants Est. completion 2028-01-31 1 site Stand-alone
    Other conditions: Solid Tumor Cancer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Olanzapine, Olanzapine 2.5Mg Oral Tablet, Apo-Olanzapine

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.